⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OSTX News
OS Therapies Incorporated
Form 8-K
sec.gov
OSTX
Rubenstein Public Relations Named Agency of Record for OS Therapies
globenewswire.com
OSTX
Form 8-K
sec.gov
OSTX
PTHS
EDVA
BLNE
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing Ready to Announce with Confidence?
newsfilecorp.com
OSTX
Form 8-K
sec.gov
OSTX
Form 8-K
sec.gov
OSTX
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial Ready to Announce with Confidence?
newsfilecorp.com
OSTX